CORRECTION – OpGen Reports Fourth Quarter and Full Year

ROCKVILLE, Md., March 30, 2023 (GLOBE NEWSWIRE) -- In a release published March 29, 2023 under the same headline by OpGen, Inc. (Nasdaq: OPGN), the...

Related Keywords

Vienna ,Wien ,Austria ,China ,Ukraine ,Beijing ,Russia ,Chinese ,Oliver Schacht ,Curetis Gmb ,Albert Weber ,Gene Panel ,Opgen Investor Press Contact ,Edison Group ,European Investment Bank ,International Number ,Exchange Commission ,Securities Exchange ,Technology Platform ,Opgen Inc ,Nasdaq ,Foundation For Innovative New Diagnostics ,Full Year ,Chief Financial Officer ,Beijing Clear Biotech ,Ares Genetics ,Innovative New Diagnostics ,Dial In Number ,United Statesa ,Curetis Gmbh ,Ares Genetics Gmbh ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,Nasdaq Capital Market ,Gen Investor ,Press Contact ,Months Ended December ,Ended December ,Nasdaq Opgn ,Opgen ,Nc ,Earnings ,Business Update ,Revenue ,Completion ,Uccessful ,Commercial ,Ti ,Fda ,Clinical Trial ,Data Readout ,Ebinar ,De Novo ,023 ,Hospital ,